Please assess the completion status of the following clinical trial:

Trial Title: Convalescent Plasma to Limit SARS-CoV-2 Associated Complications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years of age~* Competent and capable to provide informed consent~* • Positive molecular test for presence of SARS-CoV-2 in fluid collected by saliva for antigen, oropharyngeal or nasopharyngeal swab~* Experiencing any symptoms of COVID-19 including but not limited to fever(T\> 100.5º F), cough, or other COVID associated symptoms like anosmia~* ≤ 8 days since the first symptoms of COVID-19~* ≤ 8 days since first positive SARS-CoV-2 RNA test~* Able and willing to comply with protocol requirements listed in the informed consent~Exclusion Criteria:~* Hospitalized or expected to be hospitalized within 24 hours of enrollment~* Psychiatric or cognitive illness or recreational drug/alcohol use that in the opinion of the principal investigator, would affect subject safety and/or compliance~* History of prior reactions to transfusion blood products~* Inability to complete therapy with the study product within 24 hours after enrollment~* Receiving any treatment drug for COVID-19 within 14 days prior to screening evaluation (monoclonal antibodies, compassionate use or study trial related). Steroid treatment at any time does not affect study eligibility

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SARS-CoV-2 convalescent plasma (Type: EXPERIMENTAL): SARS-CoV-2 convalescent plasma (1 cup; minimum of 175 mL collected by apheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320 and after July 2021 meets FDA criteria for high titer plasma.
- Standard Control plasma (Type: ACTIVE_COMPARATOR): Plasma collected from a volunteer donor prior to January 1, 2020 will not be tested for SARS-CoV-2 antibodies. Plasma collected after December 31, 2019 will be confirmed as SARS-CoV-2 seronegative.

Based on this trial design, predict the completion outcome and termination type (if applicable).